– Interim analysis of B-Clear clinical study of bepirovirsen demonstrated end-of-treatment virologic response (VR) in patients with chronic hepatitis B – Phase 3 clinical study evaluating bepirovirsen as a monotherapy is anticipated to start in the first half of 2023 – GSK to explore…